STANDARD BIOTOOLS INC. — Director's Dealing 2011

Feb 16, 2011

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: FLUIDIGM CORP (FLDM)
CIK: 0001162194
Period of Report: 2011-02-14

Reporting Person: Loh Jeremy (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2011-02-15	Common Stock	C	1047955	—	Acquired	1047955	Indirect
2011-02-15	Common Stock	C	623531	—	Acquired	1671486	Indirect
2011-02-15	Common Stock	C	128025	—	Acquired	1799511	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2011-02-15	Series E Preferred Stock	$	C	1047955	Disposed		Common Stock (1047955)	Indirect
2011-02-15	Series D Preferred Stock	$	C	623531	Disposed		Common Stock (623531)	Indirect
2011-02-15	Series C Preferred Stock	$	C	128025	Disposed		Common Stock (125025)	Indirect

Footnotes

F1: Represents shares of Common Stock issued upon conversion of shares of Series E Preferred Stock on a 1-for 1.300053676865 basis.

F2: Not applicable.

F3: Biomedical Sciences Investment Fund Pte Ltd is the record holder of the securities reported.

F4: EDB Investments Pte Ltd, or EDB Investments, is the parent entity of Biomedical Sciences Investment Fund Pte Ltd and Singapore Bio-Innovations Pte Ltd. The Economic Development Board of Singapore, or EDB, is the parent entity of EDB Investments. EDB is a Singapore government entity. EDB Investments, EDB and the Singapore government may be deemed to have shared voting and dispositive power over the shares owned beneficially and of record by Biomedical Sciences Investment Fund Pte Ltd and Singapore Bio-Innovations Pte Ltd. Jeremy Loh, the reporting person, is one of the Issuer's directors and a Vice President (Investments), San Francisco Center for EDB Investments Pte Ltd, Singapore. Dr. Loh disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

F5: Represents shares of Common Stock issued upon the conversion of shares of Series C Preferred Stock and Series D Preferred Stock on a 1-for-1 basis.

F6: Singapore Bio-Innovations Ptd Ltd is the record holder of the securities reported.

F7: Each share of Series E Preferred Stock converted into 1.300053676865 share of Common Stock on February 15, 2011 and has no expiration date.

F8: Each share of Series C Preferred Stock or Series D Preferred Stock converted into one share of Common Stock on February 15, 2011 and has no expiration date.